-
Something wrong with this record ?
Enzyme Tunnels and Gates As Relevant Targets in Drug Design
SM. Marques, L. Daniel, T. Buryska, Z. Prokop, J. Brezovsky, J. Damborsky,
Language English Country United States
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
27957758
DOI
10.1002/med.21430
Knihovny.cz E-resources
- MeSH
- Molecular Targeted Therapy * MeSH
- Enzymes metabolism MeSH
- Humans MeSH
- Models, Molecular MeSH
- Drug Design MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Many enzymes contain tunnels and gates that are essential to their function. Gates reversibly switch between open and closed conformations and thereby control the traffic of small molecules-substrates, products, ions, and solvent molecules-into and out of the enzyme's structure via molecular tunnels. Many transient tunnels and gates undoubtedly remain to be identified, and their functional roles and utility as potential drug targets have received comparatively little attention. Here, we describe a set of general concepts relating to the structural properties, function, and classification of these interesting structural features. In addition, we highlight the potential of enzyme tunnels and gates as targets for the binding of small molecules. The different types of binding that are possible and the potential pharmacological benefits of such targeting are discussed. Twelve examples of ligands bound to the tunnels and/or gates of clinically relevant enzymes are used to illustrate the different binding modes and to explain some new strategies for drug design. Such strategies could potentially help to overcome some of the problems facing medicinal chemists and lead to the discovery of more effective drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025229
- 003
- CZ-PrNML
- 005
- 20180716122802.0
- 007
- ta
- 008
- 180709s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/med.21430 $2 doi
- 035 __
- $a (PubMed)27957758
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Marques, Sergio M $u Loschmidt Laboratories, Faculty of Science, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, RECETOX, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
- 245 10
- $a Enzyme Tunnels and Gates As Relevant Targets in Drug Design / $c SM. Marques, L. Daniel, T. Buryska, Z. Prokop, J. Brezovsky, J. Damborsky,
- 520 9_
- $a Many enzymes contain tunnels and gates that are essential to their function. Gates reversibly switch between open and closed conformations and thereby control the traffic of small molecules-substrates, products, ions, and solvent molecules-into and out of the enzyme's structure via molecular tunnels. Many transient tunnels and gates undoubtedly remain to be identified, and their functional roles and utility as potential drug targets have received comparatively little attention. Here, we describe a set of general concepts relating to the structural properties, function, and classification of these interesting structural features. In addition, we highlight the potential of enzyme tunnels and gates as targets for the binding of small molecules. The different types of binding that are possible and the potential pharmacological benefits of such targeting are discussed. Twelve examples of ligands bound to the tunnels and/or gates of clinically relevant enzymes are used to illustrate the different binding modes and to explain some new strategies for drug design. Such strategies could potentially help to overcome some of the problems facing medicinal chemists and lead to the discovery of more effective drugs.
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a enzymy $x metabolismus $7 D004798
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární modely $7 D008958
- 650 12
- $a cílená molekulární terapie $7 D058990
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Daniel, Lukas $u Loschmidt Laboratories, Faculty of Science, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, RECETOX, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. International Centre for Clinical Research, St. Anne's University Hospital, Pekarska 53, 656 91, Brno, Czech Republic.
- 700 1_
- $a Buryska, Tomas $u Loschmidt Laboratories, Faculty of Science, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, RECETOX, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. International Centre for Clinical Research, St. Anne's University Hospital, Pekarska 53, 656 91, Brno, Czech Republic.
- 700 1_
- $a Prokop, Zbynek $u Loschmidt Laboratories, Faculty of Science, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, RECETOX, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. International Centre for Clinical Research, St. Anne's University Hospital, Pekarska 53, 656 91, Brno, Czech Republic.
- 700 1_
- $a Brezovsky, Jan $u Loschmidt Laboratories, Faculty of Science, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, RECETOX, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. International Centre for Clinical Research, St. Anne's University Hospital, Pekarska 53, 656 91, Brno, Czech Republic.
- 700 1_
- $a Damborsky, Jiri $u Loschmidt Laboratories, Faculty of Science, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, RECETOX, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. International Centre for Clinical Research, St. Anne's University Hospital, Pekarska 53, 656 91, Brno, Czech Republic.
- 773 0_
- $w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 37, č. 5 (2017), s. 1095-1139
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27957758 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180716123100 $b ABA008
- 999 __
- $a ok $b bmc $g 1317360 $s 1022150
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 37 $c 5 $d 1095-1139 $e 20161213 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
- LZP __
- $a Pubmed-20180709